Rivaroxaban treatment for six weeks versus three months in patients with symptomatic isolated distal deep vein thrombosis: randomised controlled trial.

ABSTRACT:

Objective

To compare two different treatment durations of rivaroxaban in patients with symptomatic isolated distal deep vein thrombosis (DVT).

Design

Randomised, double blind, placebo controlled clinical trial.

Setting

28 outpatient clinics specialising in venous thromboembolism.

Participants

402 adults (≥18 years) with symptomatic isolated distal DVT.

Interventions

After receiving standard dose rivaroxaban for six weeks, participants were randomly assigned to receive rivaroxaban 20 mg or placebo once daily for an additional six weeks. Follow-up was for 24 months from study inclusion.

Main outcomes measures

The primary efficacy outcome was recurrent venous thromboembolism during follow-up after randomisation, defined as the composite of progressio

SUBMITTER: Ageno W 

PROVIDER: S-EPMC9682494 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature